vs

Side-by-side financial comparison of PAR TECHNOLOGY CORP (PAR) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $120.1M, roughly 1.7× PAR TECHNOLOGY CORP). On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 14.4%). PAR TECHNOLOGY CORP produced more free cash flow last quarter ($-12.5M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 30.9%).

PAR Technology Corp is a global provider of point-of-sale systems, restaurant management software, and integrated tech solutions. Its core segments serve food service, hospitality, and government security markets, offering cloud tools to streamline operations, enhance customer experiences, and boost efficiency for enterprise and small-to-medium clients.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

PAR vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
1.7× larger
RARE
$207.3M
$120.1M
PAR
Growing faster (revenue YoY)
RARE
RARE
+11.5% gap
RARE
25.9%
14.4%
PAR
More free cash flow
PAR
PAR
$88.2M more FCF
PAR
$-12.5M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
30.9%
PAR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PAR
PAR
RARE
RARE
Revenue
$120.1M
$207.3M
Net Profit
$-128.6M
Gross Margin
41.2%
Operating Margin
-15.0%
-54.7%
Net Margin
-62.0%
Revenue YoY
14.4%
25.9%
Net Profit YoY
3.5%
EPS (diluted)
$-0.52
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PAR
PAR
RARE
RARE
Q4 25
$120.1M
$207.3M
Q3 25
$119.2M
$159.9M
Q2 25
$112.4M
$166.5M
Q1 25
$103.9M
$139.3M
Q4 24
$105.0M
$164.6M
Q3 24
$96.8M
$139.5M
Q2 24
$78.2M
$147.0M
Q1 24
$70.1M
$108.8M
Net Profit
PAR
PAR
RARE
RARE
Q4 25
$-128.6M
Q3 25
$-18.2M
$-180.4M
Q2 25
$-21.0M
$-115.0M
Q1 25
$-24.4M
$-151.1M
Q4 24
$-133.2M
Q3 24
$-19.8M
$-133.5M
Q2 24
$54.2M
$-131.6M
Q1 24
$-18.3M
$-170.7M
Gross Margin
PAR
PAR
RARE
RARE
Q4 25
41.2%
Q3 25
41.3%
Q2 25
45.4%
Q1 25
46.5%
Q4 24
42.9%
Q3 24
44.5%
Q2 24
41.0%
Q1 24
37.2%
Operating Margin
PAR
PAR
RARE
RARE
Q4 25
-15.0%
-54.7%
Q3 25
-14.8%
-106.9%
Q2 25
-15.4%
-64.8%
Q1 25
-15.2%
-102.6%
Q4 24
-15.6%
-74.3%
Q3 24
-15.7%
-94.6%
Q2 24
-26.5%
-79.1%
Q1 24
-38.2%
-151.9%
Net Margin
PAR
PAR
RARE
RARE
Q4 25
-62.0%
Q3 25
-15.3%
-112.8%
Q2 25
-18.7%
-69.0%
Q1 25
-23.4%
-108.5%
Q4 24
-80.9%
Q3 24
-20.5%
-95.7%
Q2 24
69.3%
-89.5%
Q1 24
-26.1%
-156.8%
EPS (diluted)
PAR
PAR
RARE
RARE
Q4 25
$-0.52
$-1.28
Q3 25
$-0.45
$-1.81
Q2 25
$-0.52
$-1.17
Q1 25
$-0.60
$-1.57
Q4 24
$-0.56
$-1.34
Q3 24
$-0.56
$-1.40
Q2 24
$1.60
$-1.52
Q1 24
$-0.62
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PAR
PAR
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$80.1M
$421.0M
Total DebtLower is stronger
$394.0M
Stockholders' EquityBook value
$825.1M
$-80.0M
Total Assets
$1.4B
$1.5B
Debt / EquityLower = less leverage
0.48×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PAR
PAR
RARE
RARE
Q4 25
$80.1M
$421.0M
Q3 25
$93.0M
$202.5M
Q2 25
$85.7M
$176.3M
Q1 25
$92.2M
$127.1M
Q4 24
$108.6M
$174.0M
Q3 24
$118.4M
$150.6M
Q2 24
$142.5M
$480.7M
Q1 24
$72.5M
$112.3M
Total Debt
PAR
PAR
RARE
RARE
Q4 25
$394.0M
Q3 25
$393.4M
Q2 25
$392.8M
Q1 25
$392.3M
Q4 24
$368.4M
Q3 24
$466.7M
Q2 24
$378.7M
Q1 24
$378.2M
Stockholders' Equity
PAR
PAR
RARE
RARE
Q4 25
$825.1M
$-80.0M
Q3 25
$838.0M
$9.2M
Q2 25
$859.1M
$151.3M
Q1 25
$852.0M
$144.2M
Q4 24
$871.7M
$255.0M
Q3 24
$692.7M
$346.8M
Q2 24
$588.3M
$432.4M
Q1 24
$526.4M
$140.3M
Total Assets
PAR
PAR
RARE
RARE
Q4 25
$1.4B
$1.5B
Q3 25
$1.4B
$1.2B
Q2 25
$1.4B
$1.3B
Q1 25
$1.4B
$1.3B
Q4 24
$1.4B
$1.5B
Q3 24
$1.3B
$1.5B
Q2 24
$1.1B
$1.6B
Q1 24
$1.0B
$1.3B
Debt / Equity
PAR
PAR
RARE
RARE
Q4 25
0.48×
Q3 25
0.47×
Q2 25
0.46×
Q1 25
0.46×
Q4 24
0.42×
Q3 24
0.67×
Q2 24
0.64×
Q1 24
0.72×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PAR
PAR
RARE
RARE
Operating Cash FlowLast quarter
$-11.8M
$-99.8M
Free Cash FlowOCF − Capex
$-12.5M
$-100.8M
FCF MarginFCF / Revenue
-10.4%
-48.6%
Capex IntensityCapex / Revenue
0.7%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-30.5M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PAR
PAR
RARE
RARE
Q4 25
$-11.8M
$-99.8M
Q3 25
$8.4M
$-91.4M
Q2 25
$-6.6M
$-108.3M
Q1 25
$-17.2M
$-166.5M
Q4 24
$3.4M
$-79.3M
Q3 24
$8.8M
$-67.0M
Q2 24
$-13.8M
$-77.0M
Q1 24
$-23.6M
$-190.7M
Free Cash Flow
PAR
PAR
RARE
RARE
Q4 25
$-12.5M
$-100.8M
Q3 25
$7.0M
$-92.7M
Q2 25
$-7.4M
$-110.7M
Q1 25
$-17.6M
$-167.8M
Q4 24
$3.2M
$-79.5M
Q3 24
$8.4M
$-68.6M
Q2 24
$-14.2M
$-79.0M
Q1 24
$-23.6M
$-193.9M
FCF Margin
PAR
PAR
RARE
RARE
Q4 25
-10.4%
-48.6%
Q3 25
5.9%
-58.0%
Q2 25
-6.6%
-66.5%
Q1 25
-16.9%
-120.5%
Q4 24
3.0%
-48.3%
Q3 24
8.7%
-49.2%
Q2 24
-18.2%
-53.7%
Q1 24
-33.7%
-178.2%
Capex Intensity
PAR
PAR
RARE
RARE
Q4 25
0.7%
0.5%
Q3 25
1.1%
0.8%
Q2 25
0.7%
1.5%
Q1 25
0.4%
1.0%
Q4 24
0.2%
0.1%
Q3 24
0.4%
1.2%
Q2 24
0.5%
1.4%
Q1 24
0.1%
3.0%
Cash Conversion
PAR
PAR
RARE
RARE
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
-0.26×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PAR
PAR

Subscription Service$76.1M63%
Hardware$27.8M23%
Professional Service$16.2M13%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons